(A) regulation of adenylyl cyclase activity by G s -and G i -coupled G-protein-coupled receptors. (B) principle of the cyclic adenosine monophosphate (cAMp)-quenching resonance energy transfer assay. An increasing level of intracellular cAMp is observed upon agonistmediated activation of a G s -coupled receptor. in the assay, endogeneous cAMp binds to the cAMp-specific antibody after cell lysis and prevents europium(iii)-labeled cAMp from binding to the antibody. A reduced time-resolved fluorescence signal is monitored as the labeled cAMp is quenched in solution with soluble quenchers. When no receptor activation occurs, the labeled cAMp binds to the antibody, and a high signal is detected. A decreasing level of intracellular cAMp is measured following simultaneous adenylyl cyclase stimulation by forskolin and agonistmediated activation of a G i -coupled receptor.
We have developed a novel homogeneous high-throughput screening (Hts) assay feasible for measuring cAMp in intact cells. the assay is based on the quenching resonance energy transfer (Qret) technique [11] [12] [13] using a single-label approach and soluble quenchers affecting the fluorescence of the unbound labeled binding component. less fluorescence quenching is observed when the labeled component binds to an antibody. the assay is based on the nonlabeled intracellular cAMp and exogenously added eu-labeled cAMp, which compete for binding to the anti-cAMp antibody after cell lysis (Fig. 1B) . stably transfected human embryonic kidney (HeK) 293 i cells overexpressing human β 2 -adrenergic receptors (β 2 Ar, coupled to G s ) or human δ-opioid receptors (δor; coupled to G i ) were used as model systems.
MAtErIALS And MEtHodS
Materials dulbecco's Modified eagle's Medium (dMeM) with high glucose, fetal bovine serum (FBs), penicillin/streptomycin solution, l-glutamine, and trypsin/edtA solution was purchased from euroclone (Milano, italy). Blasticidin s and hygromycin were from invitrogen (carlsbad, cA). tetracycline, forskolin, 3-isobutyl-1-methylxanthine (iBMX), γ-globulin, and the β 2 Ar agonists metaproterenol, terbutaline, and epinephrine were obtained from sigma-Aldrich (st. louis, Mo). phosphate-buffered saline (1×pBs) for cell culture was obtained from lonza (Basel, switzerland). the δor agonist snc-80 [(+)-4-[(αr)-α-((2s,5r)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-n,n,-diethylbenzamidin] was purchased from tocris (ellisville, Mo). triton X-100 was from Fluka (Buchs, switzerland). the quencher was obtained from Qret technologies (turku, Finland). Anti cAMp antiserum, europium(iii)-labeled cAMp (cAMp-eu), Ad0262 lAnthanide chelation excitation (lAnce) cAMp 384 kit, and optiplate 384F were obtained from perkinelmer, Wallac (turku, Finland).
Cell culture
preparation of stably transfected HeK293 i cell lines overexpressing human β 2 Ars or human δors by transfecting Flp-in-293 cells (invitrogen) have been described elsewhere. 14, 15 We used δor construct codes as receptor carrying phenylalanine at position 27. 15 cells were cultured in dMeM, containing 10% FBs, 100 u ml −1 penicillin, 0.1 mg ml −1 streptomycin, 2 mM l-glutamine, 1 µg ml −1 blasticidin, and 100 µg ml −1 hygromycin in a humidified atmosphere of 5% co 2 at 37 °c. cells were cultured to 80% to 90% confluency in 100-mm culture plates and then passaged approximately every 3 days with the use of trypsin/edtA solution. the δor cells were induced to express the receptor at 50% to 60% confluency by adding 0.5 µg ml −1 tetracycline to the growth medium 24 h before harvesting. the β 2 Ar cells were not inducing due to the loss of the tet repressor expression. these cells express the receptor in a constitutive manner (~7 pmol/mg). 14 cAMP assays cells overexpressing β 2 Ars were cultured to near confluency on 10-cm culture plates, harvested in the growth medium with a scraper, and washed once with the growth medium and counted under a microscope after centrifugation (100 × g, 5 min). For the experiment, the cell growth medium was changed to the stimulation buffer containing 0.16 mM iBMX and 1 mg ml −1 γ-globulin in pBs. to a 384-microplate, 6 µl of the stimulation buffer including metaproterenol at concentrations of 0.1 or 100 nM, 6 µl of the cell suspension with a varying number of cells (1000, 3000, 6000, 9000, or 12 000 cells per well), and the anti cAMp antibody (3 nM) were added. the reaction mixture was incubated for 30 min at room temperature in the dark with gentle shaking. thereafter, 12 µl of detection buffer including 1.5 nM cAMp-eu, 12 mg ml −1 triton X-100, and the quencher in 50 mM Hepes pH 7.4 was added, and the final reaction solution was incubated for another 20 min at room temperature in the dark with gentle shaking to achieve the reaction equilibrium. the time-gated fluorescence signal was measured at 615 nm using 340-nm excitation wavelength, 400-µs delay, and 400-µs integration times with a Victor 2 1420 multilabel counter (perkinelmer, Wallac).
For the agonist stimulation assay, cells were cultured and assayed using the same protocol as above with 9000 cells per reaction. Varying concentrations (0.003-10 000 nM) of metaproterenol, terbutaline, or epinephrine were added in the stimulation buffer to activate β 2 Ar. For the measurement of the cAMp calibration curve, the same assay conditions were applied without added agonists or cells using exogenously added cAMp at concentrations from 0.1 to 10 000 nM. the developed Qret assay was compared with the timeresolved fluorescence resonance energy transfer (tr-Fret) lAnce cAMp 384 assay from perkinelmer for their assay parameters. the same assay protocol was adapted to the Qret assay as above. the lAnce assays were carried out according to the manufacturer's protocol 10 in parallel with the Qret assay using the same ligand dilution for both assays. Metaproterenol-mediated stimulation of β 2 Ar was monitored at concentrations from 0.011 to 10 000 nM. Adenylyl cyclase was chemically activated with forskolin at concentrations from 1 to 100 000 nM in addition to receptor stimulation. the statistical Z′ value is commonly used as an indicator of assay robustness and value should exceed 0.5 to be adaptable to Hts. the Z′ values were calculated for both experiments by using the equation 1-[(3σ max + 3σ min ) / (|µ max -µ min |)], where µ is the signal mean and σ the standard deviation. 16 upon activation of G i -coupled receptors, the adenylyl cyclase activity was reduced. this was tested using the HeK293 i cell line overexpressing δors. cells were cultured and harvested in the same manner as the cells overexpressing β 2 Ars. the stimulation buffer contained both 10 µM forskolin and the δor agonist snc-80 at concentrations ranging from 0.03 to 30 nM. the assay conditions were the same as described above for β 2 Ar using 9000 cells per reaction.
rESuLtS
the principle of the cAMp-Qret assay is outlined in Figure 1B . Agonist-mediated activation of Gpcrs coupled to either the stimulatory G s protein (β 2 Ar) or the inhibitory G i protein (δor) leads to modulation of adenylyl cyclase activity and cAMp production. in the Qret assay, the endogenous cAMp competes with the exogenously added eu-labeled cAMp for binding to the cAMp-specific antibody, and a high fluorescence signal is observed when the eu-labeled cAMp binds to the antibody. this occurs when adenylyl cyclase is activated via β 2 Ar and intracellular cAMp levels are increased. in comparison, an increased fluorescence signal is detected following inactivation of adenylyl cyclase via δor, which reduces the intracellular cAMp production. the fluorescence of the unbound eu-labeled cAMp is efficiently quenched in solution by a soluble quencher. High fluorescence signal corresponds to low cAMp concentration and the low signal to high cAMp concentration because of the competitive nature of the assay. prior to Gpcr activation by receptor-specific agonists, we measured the calibration curve for cAMp at equilibrium under optimized conditions. this was carried out using increasing concentrations of added cAMp (0.1-10 000 nM) in a biochemical system without cells (Fig. 2) . the ec 50 , signal-to-background (s/B) ratio, and the average assay signal variability (cV) were 44 nM, 12.6 and 5.1%, respectively. Varying concentrations of dMso (0-10 % of the assay total volume) was tested in the developed assay. When dMso concentration increased from 0 to 10 %, the time-resolved fluorescence signal decreased by 24% and increased by 27% at 0 and 10 µM concentrations, respectively (see Supplementary Information).
Cell number optimization for the QRET assay
the cAMp assay was developed for a stably transfected HeK293 i cell line overexpressing human β 2 Ars. the number of cells required for the cAMp-Qret assay was assessed by stimulating the receptor with an agonist metaproterenol at concentrations of 0.1 and 100 nM (Fig. 3) . the saturation of the s/B ratio was identical at cell counts higher than 3000 cells per assay for both tested ligand concentrations. this led us to employ 9000 cells in a reaction in all subsequent experiments.
The cAMP-QRET assay and G s -coupled β 2 AR
the functionality of the developed cAMp method was assayed using β 2 Ar-expressing HeK293 i cells that were stimulated with β 2 Ar agonists with differing efficacies and potencies: epinephrine, metaproterenol, and terbutaline. As expected, both the ec 50 and e max values differed for the three ligands tested. the ec 50 values were 0.056, 3.6 and 2.9 nM and the detection limits (90% of signal) 4.2, 450 and 400 pM for epinephrine, metaproterenol, and terbutaline, respectively (Fig. 4) . epinephrine acted as a full agonist having the highest e max value. the partial agonists metaproterenol and terbutaline had e max values that were 75 and 74% of that of epinephrine, respectively. the signal variability (cV) of the assays varied from 1 to 15 %.
Comparison of the QRET and TR-FRET methods
to compare the developed Qret assay with the commercial lAnce assay, the effect of the adenylyl cyclase activator forskolin on intracellular concentrations of cAMp was measured. the adenylyl cyclase in β 2 Ar expressing HeK293 i cells was stimulated by varying concentrations of forskolin (1-30 000 nM) and changes in the time-resolved fluorescence signal were monitored. Following the commercial lAnce kit protocol and the optimized assay conditions for the Qret method, the assays were performed in parallel using the same forskolin solutions (Fig. 5) . the ec 50 values of 89 and 32 nM, the detection limits of 6.6 and 6.3 nM and the s/B ratios of 5.1 and 3.3 were calculated for the Qret and the lAnce assays, respectively ( Fig. 5) . this indicates that both methods measure cellbased cAMp levels with high efficiency. the Z′ values were calculated to study the robustness of the assay. the Z′ values for the Qret and lAnce assays were 0.72 and 0.85, respectively. the signal variability for the Qret assay varied from 1 to 12 % and for the lAnce assay from 1 to 7 %. the functionality of the Qret and tr-Fret cAMp assays were further investigated and compared in a cell-based assay, in which β 2 Ars were activated by the partial agonist metaproterenol ( Fig. 6) . the ec 50 value for the Qret assay was 3.2 nM and the detection limit was 0.35 nM; for the lAnce assay, the ec 50 value was 1.5 nM and the detection limit was 0.42 nM (Fig 6.) . the signal imprecision for the Qret assay was from 0 to 12 % giving a Z′ value of 0.76, and the s/B ratio was 4.5. the corresponding values for the lAnce assay were 1-3 % for cV, 0.95 for the Z′ value and 3.3 for the s/B ratio.
The cAMP-QRET assay and G i -coupled δOR
Having proven the capability of the cAMp-Qret assay for a G s -coupled Gpcr that stimulates adenylyl cyclase, assay parameters were investigated for an inhibitory G i -coupled Gpcr. to this end, the response of stably transfected HeK293 i cells overexpressing human δors to a selective opioid agonist snc-80 was measured. cells were incubated with increasing concentrations of agonist in the presence of 10 µM forskolin to enhance the response window. As expected, an increasing fluorescence signal was observed upon snc-80 activation of the receptor (Fig. 7) , proving the negative effect on cAMp production. the ec 50 value of 0.68 nM was measured for snc-80 and the signal variability varied from 1 to 15%. dIScuSSIon previously, the potential of the Qret technique has been demonstrated for receptor-ligand and Gtp binding studies on cells and cell membranes. 11, 13 Here we have developed a cellbased homogeneous assay for the second messenger, cAMp, using a time-resolved fluorescence single-label approach. the cAMp assay was developed using a stably transfected HeK293 i cell line overexpressing human β 2 Ars. the number of receptors 240 000 per cell was determined previously in a saturation ligand-binding assay for the cell line. 14 in this study, the optimized cell count in an assay was investigated, and 3000 cells per assay were sufficient to obtain saturation of s/B ratio although 9000 cells in a reaction were eventually employed. dMso tolerance is one of the important parameters needed in the evaluation any method for the Hts use. our data suggests that dMso is well tolerated by the cAMp immunoreaction. to test the functionality of the assay. the agonists were investigated at 0.03 to 10 000 nM concentrations. the ec 50 values were 0.056, 3.6, and 2.9 nM, and the detection limits were 7.5, 610, and 536 pM for epinephrine, metaproterenol, and terbutaline, respectively. the cell-based Qret method has also been shown to tolerate dMso well in a receptor-ligand binding assay. 11 Hts applications also require stable signal to enable off-line detection. this has been studied in a cell-based Qret method earlier, and a stable signal up to 72 hours has been reported. 11 the feasibility of the developed method was proven by comparing the assay performance with the commercial homogeneous tr-Fret assay (lAnce cAMp kit from perkinelmer). the choice of the reference method is justified because the two techniques share the same detection features: excitation at 340 nm and time-resolved fluorescence detection above 600 nm with a temporal resolution leading to reduced background fluorescence. this also enables the use of a single instrument equipped with a red sensitive detector for both assays, although different emission filter setups must be applied. tr-Fret-based homogeneous assays have been proven to be one of the most sensitive and applied methods for the measurement of intracellular cAMp levels, enabling a direct evaluation of the developed method for Hts use. 17 the performance of the developed assay was similar to the commercial assay whether adenylyl cyclase was stimulated directly with forskolin or β 2 Ar was stimulated with agonists. the obtained ec 50 values for the agonists are in accordance with those reported in previous studies. [18] [19] [20] Minor differences in the concentration response curves and calculated assay parameters were considered insignificant. this is not surprising as the same cAMp-specific antibody was applied in both assays.
the functionality of the cAMp-Qret assay was further proved in the inhibitory G i -coupled Gpcr model. the response of the stably transfected HeK293 i cells overexpressing human δor to a selective opioid agonist snc-80 was successfully measured. the determined ec 50 value of 0.65 nM was comparable to previously reported values in other heterologous expression systems. [21] [22] [23] the main advantage of the Qret assay is the use of a single label, making this method more cost-effective for assay development and end-users. in this particular tr-Fret assay, labeling of the soluble antibody is relatively straightforward but requires optimization, adding extra efforts to the assay development. However, in homogeneous methods such as cell-based receptor-ligand and Gtp-binding assays, the distance-dependent approach is not readily applicable because membrane-embedded receptors may not be accessible to labeling or highly specific antibodies are difficult to produce to target molecules such as Gtp. labeling procedures always add another factor of variation between batches, including possible reduction of binding sites (e.g., of the cAMp antibody). these assay-related problems can be solved using a single-label approach. We have previously demonstrated that receptor-ligand and Gtp binding assays can be constructed on the Qret concept. 11, 13 Fluorescence polarization is another known single-label approach for drug-screening purposes. However, the drawback of this method is the use of conventional fluorescence having 3-4 orders of magnitude less sensitive detection limit than timeresolved fluorescence 24 and a low s/B ratio, 4, 12, 25, 26 reducing the applicability of the method for many target molecules.
in conclusion, the changes in intracellular cAMp levels were successfully measured following agonist activation of both G s -and G i -coupled Gpcrs using the single-label Qret technique. the developed assay requires no separation or washing steps, making it simple and fast to use and highly suitable to Hts. the single-label approach of the Qret technique provides a powerful tool for screening purposes in a cost-effective manner as there is no need for labeling of a accumulation by snc-80 in HeK293 i cells overexpressing the G i -coupled δ-opioid receptors (δor). the cAMp production by activation of adenylyl cyclase with forskolin (10 µM) was inhibited with increasing concentrations (0.03-30 nM) of the δor-specific agonist snc-80. the ec 50 value of 0.68 nM and the detection limit of 0.1 nM were calculated for the inhibition curve. receptor or antibody, reducing optimization steps and cost of the assay. the feasibility of the method was proven in a comparative study with the commercial lAnce cAMp method. similar parameters for both assays were measured for the β 2 Ar agonist-and forskolin-mediated stimulation of adenylyl cyclase. this is the first demonstration of the Qret method in a cell-based signal transduction assay with assay parameters equal to well-established commercial methods, showing its capability for efficient monitoring of intracellular events.
